News
-
Alliance
C4U Corporation has raised a total of 1.5 billion JPY (approximately $11 million at the then-effective exchange rate) for its Series B financing.
-
Information
Our researcher will give a poster presentation at the Keystone Symposia on Molecular and Cellular Biology “Precision Genome Engineering”, in Whistler, Canada, from March 19-23, 2023.
-
Alliance
C4U and Brain Research Institute, Niigata University have entered into the collaborative research agreement for a novel gene therapy utilizing CRISPR -Cas3 technology.
-
R&D
The paper “Dynamic mechanisms of CRISPR interference by Escherichia coli CRISPR-Cas3” was published in Nature Communications.
-
Alliance
C4U and Sumitomo Dainippon Pharma enter into Collaborative Research and Alliance Agreement
-
Alliance
C4U and Logomix have entered into the joint research agreement on applying CRISPR-Cas3 genome editing technology to Logomix’s Geno-WritingTM technology.
-
Alliance
C4U and the Center for iPS Cell Research and Application(CiRA), Kyoto University have conducted a joint research since January 2020 to promote the research utilizing novel genome editing technology over iPS cells.
-
R&D
The paper “CRISPR-Cas3-based diagnostics for SARS-CoV-2 and influenza virus” was published in iScience.
-
R&D
C4U and Sumitomo Dainippon Pharma enter into the Next Stage of Joint Research
-
Alliance
C4U, the Division of Animal Genetics, the Institute of Medical Science, the University of Tokyo and Transgenic Inc. have entered into the joint research agreement for genome editing experiments using mouse model with humanized exon.